Skip to main content

Table 2 Antipsychotic preferences for different disorders at discharge (n = 981)

From: Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey

  Total MDD AD DCR OMD MDPS Dementia SMD OCD Insomnia BEDO Other
N = 981 N = 391 N = 121 N = 99 N = 93 N = 73 N = 62 N = 19 N = 18 N = 16 N = 14 N = 75
Olanzapine 29.1% 23.8%a 15.7% 55.6% 44.1% 30.1% 27.4% 42.1% 5.6% 12.5% 14.3% 33.3%
Quetiapine 20.3% 19.9%b 17.4% 21.2% 18.3% 23.3% 38.7% 15.8% 11.1% 12.5% 21.4% 14.7%
Risperidone 6.8% 2.0% 11.1% 15.1% 13.7% 14.5% 5.3% 5.6% 14.3% 14.7%
Aripiprazole 6.6% 5.9%b 2.5% 5.1% 5.4% 4.1% 1.6% 55.6% 42.9% 12.0%
Clozapine 1.9% 2.0% 2.5% 2.0% 1.1% 1.4% 1.6% 7.1% 2.7%
Other SGAs c 3.2% 2.3% 0.8% 7.1% 5.4% 5.5% 5.3% 5.3%
FGAs d 2.4% 1.8% 0.8% 3.0% 5.4% 4.1% 3.2% 5.3% 2.7%
  1. aOlanzapine and fluoxetine in combination was approved by FDA for treatment of treatment resistant depression, but not approved by CFDA
  2. bAripiprazole, quetiapine and quetiapine XR was approved by FDA as augmentation therapy for treatment resistant depression, but not approved by CFDA
  3. cOther SGAs: including amisulpride, ziprasidone, paliperidone and perospirone
  4. dFGAs: including perphenazine, haloperidol, sulpiride and chlorpromazine
  5. APs antipsychotics, MDD: major depression disorders, AD: anxiety disorder, DCR: dissociative (conversion) disorders, OMD organic mental disorders, MDPS mental disorders due to psycho active substances, SMD somatoform disorders, OCD obsessive-compulsive disorder, BEDO behavioural and emotional disorders with onset usually occurring in childhood and adolescence